What is DTIL's dilution risk score?

DTIL has a latest available DilutionScore record of 56/100, categorized as high dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for DTIL, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for DTIL?

DilutionWatch tracks 25 SEC filing types for DTIL including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect DTIL shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For DTIL, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for DTIL tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for DTIL. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

DTIL Dilution Risk Score: 56/100 (HIGH)

Score Breakdown

📋 Offering Ability

60

💰 Cash Runway

40

📊 Float Risk

40

⚠️ Warrant Exposure

40

🔄 Convertible Debt

60

Dilution Forecast

🌥️

Advisory

Moderate dilution signals present

model est. 20%

🔁 Convertible Conversion model 40%

• Significant convertible debt: 22% potential dilution

• Elevated convertible risk (60/100)

🔔 Track DTIL — Get forecast alerts →

Market Data

Market Cap$179.84M

Shares Outstanding27.60M

Float20.01M

Cash$87.55M

Debt$22.27M

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	56/100	DilutionWatch score record
Shares Outstanding	27.60M	Verified float table or market cache
Public Float	20.01M	Verified float table or market cache
Market Cap	$179.84M	Market data cache
Cash Runway	12.9 months	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	None in current score inputs	SEC-derived dilution fields
Outstanding Warrants	None in current score inputs	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 5, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 14.0% shares (2026Q1 vs prior)

78 institutional holders · 17.22M shares

#1 Octagon Capital Advisors LP 2.24M shares

#2 Aberdeen Group plc 2.23M shares

#3 Empery Asset Management, LP 1.97M shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest2.52M

Days to Cover8.4

% of Float12.6%

FINRA data as of Aug 31, 2026

Insider Buy/Sell Ratio

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31

xbrl XBRL CONVERTIBLE 2019-12-31

4 INSIDER TRANSACTION 2026-06-05

Full SEC filing analysis available with free account →

Recent News

No recent news

Factual DTIL Dilution Snapshot

Precision BioSciences, Inc. (DTIL) has a DilutionScore of 56/100, rated High dilution risk. Score date: September 12, 2026.

Recent SEC activity tracked for DTIL: 4 on 2026-06-05; 4 on 2026-06-05; 4 on 2026-06-05.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.